Compare PEBO & IOVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PEBO | IOVA |
|---|---|---|
| Founded | 1902 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 968.6M |
| IPO Year | N/A | N/A |
| Metric | PEBO | IOVA |
|---|---|---|
| Price | $30.04 | $2.75 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 6 | 12 |
| Target Price | ★ $34.58 | $10.45 |
| AVG Volume (30 Days) | 182.5K | ★ 11.5M |
| Earning Date | 01-20-2026 | 11-06-2025 |
| Dividend Yield | ★ 5.42% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.86 | N/A |
| Revenue | ★ $555,347,000.00 | $250,425,000.00 |
| Revenue This Year | N/A | $60.71 |
| Revenue Next Year | $2.59 | $59.52 |
| P/E Ratio | $10.58 | ★ N/A |
| Revenue Growth | 10.92 | ★ 175.62 |
| 52 Week Low | $26.21 | $1.64 |
| 52 Week High | $33.83 | $8.15 |
| Indicator | PEBO | IOVA |
|---|---|---|
| Relative Strength Index (RSI) | 43.33 | 63.36 |
| Support Level | $31.43 | $2.69 |
| Resistance Level | $32.03 | $2.89 |
| Average True Range (ATR) | 0.42 | 0.17 |
| MACD | -0.19 | 0.04 |
| Stochastic Oscillator | 9.57 | 75.82 |
Peoples Bancorp Inc (Marietta OH) is a financial holding company. As a community bank, it offers a complete line of banking, insurance, investment, and trust solutions through its financial subsidiaries. It offers demand deposit accounts, savings accounts, real estate mortgage loans, merchant credit card transaction processing services, corporate and personal trust services, life, health, property, and casualty insurance products, and brokerage services. The bank also offers telephone and internet-based banking through both personal computers and mobile devices.
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.